NovoCure's Current Deferred Revenue rose 432.1% to $19.6 million in Q4 2019 from the same period last year, while for Dec 2019 it was $19.6 million, marking a year-over-year increase of 432.1%. This contributed to the annual value of $19.6 million for FY2019, which is 432.1% up from last year.
According to the latest figures from Q4 2019, NovoCure's Current Deferred Revenue is $19.6 million, which was up 432.1% from $18.8 million recorded in Q4 2018.
In the past 5 years, NovoCure's Current Deferred Revenue registered a high of $19.6 million during Q4 2019, and its lowest value of $52000.0 during Q4 2015.
Over the past 5 years, NovoCure's median Current Deferred Revenue value was $5.0 million (recorded in 2017), while the average stood at $9.1 million.
As far as peak fluctuations go, NovoCure's Current Deferred Revenue skyrocketed by 425961.54% in 2016, and later soared by 432.1% in 2019.
NovoCure's Current Deferred Revenue (Quarter) stood at $52000.0 in 2015, then soared by 4259.62% to $2.3 million in 2016, then skyrocketed by 118.75% to $5.0 million in 2017, then skyrocketed by 278.48% to $18.8 million in 2018, then grew by 4.32% to $19.6 million in 2019.
Its last three reported values are $19.6 million in Q4 2019, $18.8 million for Q4 2018, and $5.0 million during Q4 2017.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value